CDK4 inhibitor p16INK4 showed upregulation in the tumor (P < 0.001) and adjacent normal tissues (P < 0.001) as well as in the Cs group (P = 0.007) but remained same in the NDMA group. The gene discussed is CDKN2A; the disease is neoplasm.